Article
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2022
Chen J, Facchinetti F, Braye F, Yurchenko A A, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen K A, Andre F, Scoazec J Y, Barlesi F, Soria J C, Loriot Y, Besse B, Friboulet L
Abstract excerpt
BACKGROUND: The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventually always occurs. In osimertinib-resistant NSCLC, the emergence of a second molecular driver alteration (such as ALK, RET, FGFR3 fusions or BRAF, KRAS mutations) has been described. Whether those alterations and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.